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treatment outcomes of ceftriaxone-resistant Salmonella will
be discussed.
doi:10.1016/j.ijid.2008.05.145
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Fluroquinolone-resistant Gonorrhea
P.R. Hsueh
National Taiwan University Hospital, Taipei, Taiwan
The rapid emergence of ﬂuoroquinolone resistance among
Neisseria gonorrhoeae isolates with a preexisting high preva-
lence of penicillin resistance in the past decade is of
great concern. The prevalence of gonococcal resistance to
ciproﬂoxacin has increased rapidly worldwide in the past
few years, but this increase has varied considerably by
country, ranging from 2.1% in Canada to 86.9% in China.
In Taiwan, ciproﬂoxacin-resistant N. gonorrhoeae was ﬁrst
isolated in 1998. A remarkable increase in the preva-
lence of ciproﬂoxacin resistance was found between 2001
(66.7%) and 2003 (95.2%) at National Taiwan University
Hospital. Previously established guidelines for the manage-
ment of gonorrhea in adults in the United States and the
United Kingdom recommended the use of a ﬂuoroquinolone
(e.g., oﬂoxacin, ciproﬂoxacin, or levoﬂoxacin) as a ﬁrst-
line option for gonorrhea therapy. Failure of gonococcal
infections caused by N. gonorrhoeae strains with resis-
tance to ciproﬂoxacin to respond to treatment with these
agents has been well documented. Accordingly, a ﬂuoro-
quinolone is no longer a ﬁrst-line option for the treatment
of gonorrhea in many countries, particularly those with
high incidence of ﬂuoroquinolone resistance in gonococcal
isolates. Spectinomycin and a cephalosporin (e.g., cefpo-
doxime or ceftriaxone) might be used as the ﬁrst-line agent
for the treatment of gonorrhea, although some gonococcal
isolates exhibiting resistance to the above agents have been
reported.
doi:10.1016/j.ijid.2008.05.146
Update on Clinically Signiﬁcant Anaerobes (invited)
61.001
Antimicrobial Resistance Among Anaerobes -The
European Experience
C.E. Nord
Karolinska Institute, Karolinska University Hospital,
Stockholm, Sweden
Clinical usage of antimicrobial agents has been accompanied
by the isolation of antimicrobial-resistant bacteria. During
the last years there have been reports showing increas-
ing numbers of anaerobic bacteria resistant to different
antimicrobial agents in Europe. Resistance in anaerobic
bacteria has a signiﬁcant impact on the selection of antimi-
crobial agents for empirical therapy. The development of
antibiotic resistance in anaerobic bacteria has been doc-
umented for beta-lactam drugs, clindamycin, macrolides,
tetracyclines, ﬂuoroquinolones and nitroimidazoles. The
Bacteroides fragilis group is more resistant to antimi-
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robial agents than most other anaerobic bacteria. The
acteroides genus and the genera Prevotella and Por-
hyromonas have become increasingly resistant to many
nti-anaerobic agents. Fusobacterium strains resistant to
eta-lactam drugs are relatively frequent. Resistant anaer-
bic cocci and Propionibacterium acnes have also been
eported. Recently, ﬂuoroquinolone-resistant Clostridium
ifﬁcile strains producing three toxins (toxin A, toxin B and
inary toxin) have been isolated from patients with severe
. difﬁcile diseases.
The resistance mechanisms in anaerobic bacteria are:
) hydrolysis of the antimicrobial drug by several enzymes
efore reaching the site of action (most common, some-
imes plasmid mediated); b) decreased permeability of the
rganisms; c) modiﬁcation at the site of action of the antimi-
robial agent; d) efﬂux mechanisms which eliminate the
ntimicrobial drug from the bacterial cell.
oi:10.1016/j.ijid.2008.05.147
1.002
lostridium difﬁcile Type O27, Coping with a More
irulent Strain
.J. Kuijper1,∗, R. Vonberg2, M. Wilcox3, P. Gastmeier4
Department of Medical Microbiology, Leiden University,
etherlands
Medical School Hannover, Hannover, Germany
Medical Microbiology, Leeds, United Kingdom
Charité University, Berlin, Germany
lostridium difﬁcile (CD) is an anaerobic bacterium capa-
le of forming spores which confer resistance to heating,
rying and chemical agents, including disinfectants. Spores
f CD may survive in the environment for long periods and
re resistant to alcohol. More than 150 PCR ribotypes and 24
oxinotypes have been recognized; epidemic ribotypes may
ave enhanced sporulation. Since 2003, increasing rates of
D infections (CDI) have been reported in North America
nd Europe involving a more severe course, higher mortal-
ty, increased risk of relapse and more complications. The
utbreaks are difﬁcult to control and require a multifaceted
pproach. The most important infection control measures
ct on interruption of transmission of spores to vulnerable
atients from infected patients and from the environ-
ent. Vulnerable patients are mainly patients who receive
ntimicrobial treatment, and therefore fewer antibiotic
rescriptions should lead to less vulnerable patients. At
resent, no sufﬁcient evidence exists to propagate the
se of probiotics to vulnerable patients for prevention
f CDI. Transmission of spores occurs mainly via contact
f contaminated health care workers to patients, directly
y patient-to-patient transmission or by transmission from
he contaminated environment to patients. There is no
irect evidence that patients or healthcare workers who are
ymptom-free but colonised with C. difﬁcile in the intestinal
ract are signiﬁcant sources of infection. Early diagnosis of
DI, prompt isolation of symptomatic patients and reduc-
ng antimicrobial treatment are essential ﬁrst steps. The
nfection control measures include recommendations to iso-
ate infected patient on a single room with designated
oilet, to apply proper hand hygiene with soap and water,
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o use appropriate protective clothing (gloves and aprons
r gowns), to intensify environmental cleaning with a chlo-
ine containing disinfectant and to take speciﬁc precautions
or the use of devices (disposable or dedicated to individ-
al patient). Patient isolation must continue at least until
iarrhoea has ceased. Each hospital should have an appro-
riate surveillance system to recognize an increase of the
ncidence of CDI in an early stage. All infection control mea-
ures should be written in a local protocol so that additional
easures can be carried out as soon as a problem with
DI arises. When outbreaks occur, additional recommenda-
ions include a reinforcement of general and hand washing
easures, intensifying of testing patients with diarrhoea
or C. difﬁcile, reinforcement of environmental cleaning,
nformation and education of health-care workers, clean-
ng department and visitors, cohorting of infected patients,
nd eventually closure of the unit followed by intensive
nvironmental cleaning. Restricted antibiotic prescribing
s also highly recommended to reduce polypharmacy and
uration of administration. Second and third generations
ephalosporins and more recently ﬂuoroquinolones have
een identiﬁed as potential risk factors. Although some hos-
itals report successes for enhanced environmental cleaning
ith potentially effective agents such as hydrogen peroxide
apour, the evidence is too scarce to consider this as an
vidence-based approach.
oi:10.1016/j.ijid.2008.05.148
1.003
olecular Biology of Protein Glycosylation in the
ymbiotic Anaerobe Bacteroides Fragilis
.M. Fletcher1,∗, M.J. Coyne1, O.F. Villa2, S. Park3,
. Azadi3, L.E. Comstock1
Brigham & Women’s Hospital and Harvard Medical School,
oston, MA, USA
Mount Sinai School of Medicine, New York, NY, USA
Complex Carbohydrate Research Center, University of
eorgia, Athens, GA, USA
. fragilis is one of the most abundant gram negative anaer-
bes living symbiotically in the human intestine, where it
igests carbohydrates for the host and has been implicated
n immune system development. It is also an opportunis-
ic pathogen and a reservoir of antibiotic resistance genes.
. fragilis produces multiple capsular polysaccharides and
ucosylated glycoproteins. Mutant strains deﬁcient in pro-
uction of either of these cannot compete with wild-type
n colonization of germ-free mice, indicating that both
ypes of molecule are vital for symbiosis. Here we char-
cterize the molecular biology of the protein glycosylation
ystem. A cell lysate was enriched for glycosylated proteins
y lectin afﬁnity chromatography and proteins identiﬁed
y mass spectrometry. These candidates were expressed
rom a plasmid in B. fragilis with a C-terminal His tag,
uriﬁed and glycosylation conﬁrmed by periodate reactivity
nd release of oligosaccharides. The glycoproteins include
secreted lipoprotein and several soluble periplasmic pro-
eins, the ﬁrst time that the latter has been observed in
bacterial species. Deletion of a genetic region contain-
ng a gene resembling an O-antigen ﬂippase and multiple
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lycosyltransferases reduced the MW of the glycoproteins,
ndicating that these genes are involved in protein glycosy-
ation and suggesting that it occurs in the periplasm. The
mallest and most abundant glycoprotein was investigated
n detail. Similar glycans were released by beta-elimination
nd hydrazinolysis, consistent with O-linkage to Ser or
hr. Point mutations in peptides that were rarely or never
bserved by mass spectrometry, and therefore likely to be
lycosylated, identiﬁed one Ser and three Thr residues as
robable glycosylation sites. Deletion of the signal peptide
revented glycosylation of the protein, consistent with it
ccurring in the periplasm. We continue to investigate the
iochemistry and genetics of the glycosylation system, the
iological functions of the glycoproteins and the role of gly-
osylation.
oi:10.1016/j.ijid.2008.05.149
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naerobes As Bioﬁlms
. Donelli 1,∗, E. Guaglianone1, R. Cardines2,
. Mastrantonio2
Department of Technologies and Health, Istituto Superiore
i Sanità, Rome, Italy
Department of Infectious, Parasitic and Immune-Mediated
iseases, Istituto Superiore di Sanità, Rome, Italy
lthough anaerobes are predominant in humans, largely out-
umbering aerobic bacteria, experimental data concerning
heir bioﬁlm forming ability are still relatively few and
ssentially focused on the anaerobic ﬂora of the mouth
including dental plaque, buccal mucosa and tongue bioﬁlm)
nd the vaginal mucosa.
As the oral environment is concerned, its complexity has
nduced the development of a number of artiﬁcial mouth
odels able to simulate the different conditions of micro-
ial growth within the microcosms of the oral cavity. With
egards to the vaginal mucosa, recent studies have eluci-
ated that the bioﬁlm phenotype confers to Gardnerella
aginalis a survival advantage in the presence of hydrogen
eroxide and lactic acid producing resident lactobacilli; on
he other hand, the ability of probiotic strains of Lactobacil-
us to interfere with Gardnerella vaginalis and disrupt its
ioﬁlm, has been recently reported as a promising tool to
educe the need for antibiotics in the treatment of bacterial
aginosis.
As the intestinal tract is concerned, investigations by
icroscopic and FISH techniques have shown that mucosal
acteria, including bacteroides and biﬁdobacteria, occur
n microcolonies and are distributed throughout the mucus
ayer.
Our group is currently investigating the role of anaerobes
n the occlusion of biliary stents. SEM observations revealed
hat biliary sludge occluding the lumen of the 18 so far
xamined polyethylene stents was constituted by a multi-
pecies (aerobes and anaerobes) microbial bioﬁlm immersed
n an amorphous material containing also dietary ﬁbers and
rystals of bile salts. The ability of the isolated anaerobic
trains, belonging to the species Bacteroides, Clostridium,
usobacterium, Peptostreptococcus, Prevotella and Veil-
onella, to form bioﬁlm has been assessed in vitro. On the
